Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome

NCT ID: NCT04503876

Last Updated: 2021-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-12

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PEEP titration is a recommended during invasive mechanical ventilation of ICU patients. However, little is known about the right way to conduct this titration. PEEP titration can be conducted by a stepwise increase in PEEP level, or following an ARM and a consecutive stepwise decrease in PEEP level. Those 2 methods will be explored in intubated ICU patients either with healthy lung or ARDS lungs. Physiological exploration will include end-expiratory lung volume measurements, driving pressure, compliance and electro-impedance tomography at each PEEP level.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Management of ICU patients may require the use of ventilatory support requiring tracheal intubation and invasive mechanical ventilation.

Any mechanically ventilated patient is exposed to the formation of atelectasis (collapsed pulmonary alveoli), which occurs systematically after endotracheal tube insertion, after any de-recruiting action (tracheal suction, disconnection) or simply if protective ventilation is used, combining small tidal volumes (6 to 8 mL/kg of theoretical ideal body weight - IBW) and an end-expiratory positive pressure (PEEP) that is sometimes insufficient. It is thus proposed to perform alveolar recruitment maneuvers (ARMs), which remove atelectasis by temporarily increasing intrathoracic pressure. To avoid alveolar re-collapse, it is necessary to apply a sufficient level of PEEP.

The opening pressure (P) necessary for the re-expansion of a collapsed alveolus is inversely proportional to its radius (r), following Laplace law P = 2.γ/r where γ is the surface tension. The pressure necessary to the re-expansion of a collapsed cell depends on its radius. Amato's team has showed in 2006 that within the same lung, several levels of alveolar aeration and thus several opening pressures coexist. The distribution of pressures was bimodal, with a peak around 30 cmH2O and a second around 40 cmH2O. Consequently, to allow complete re-expansion of atelectasis within a lung, it is necessary to apply a pressure at least equal to 30 cmH2O. The application of insufficient pressures cannot be expected to result in complete re-expansion of the lung, but rather in an increase in aeration of already aerated alveoli (whose radius is larger and whose opening pressure is much lower), what, in turn, can lead to over-distension. This is probably what can happen if the PEEP is increased without any previous ARM.

The application of an ARM can also lead to an overdistension phenomenon during a reduced period of time (20 to 30 seconds), contrary to the direct application of a high PEEP which could led to an overdistension lasting a much longer period of time (possibly several hours) and aggravated with each administration of a tidal volume (and thus several times per minute). Chronic lung exposure to overdistension phenomena can induce a disintegration of alveolar collagen fibers (volotrauma), leading to local inflammation (biotrauma) and systemic inflammation by releasing pro-inflammatory molecules (cytokines...) into the bloodstream and led to apoptosis in distant organs (kidney, digestive tract for example).

The optimization of mechanical ventilation requires the search for the optimal PEEP: insufficient, it cannot prevent atelectasis formation; too high, it would lead to alveolar overdistension. In current practice, the PEEP is determined arbitrary or following a stepwise titration, either by incremental or decremental steps. To date, scientific literature is not unequivocal concerning the use of ARMs and their safety. Thus, some teams prefer not to use ARMs and usually apply an upward PEEP level.

The concepts presented above are valid both in patients with healthy lungs and in patients with "sick" lungs, the archetype and most severe form of which is acute respiratory distress syndrome (ARDS), which is a frequent pathology in ICU (10 to 20% of patients admitted). Its definition is based on the Berlin criteria published in 2012. The morality varies between 30 and 40% depending on the severity of the respiratory impairment. Management of patients suffering from ARDS requires an optimization of oxygenation, which is based first of all on mechanical ventilation, whether invasive or not. Since the ARDS Network study published in 2000 in the New England Journal of Medicine, it has been globally accepted that tidal volumes should be reduced to no more than 6 mL/kg IBW. Ventilatory management is based on concepts of "baby lung" and "open lung". These concepts explain that it is mandatory to consider that the lung volume available for mechanical ventilation is very small compared to the healthy lung volume (baby lung) and that the reduction in tidal volume must be accompanied by adjustments to keep the lung "open", combating the formation of atelectasis by the use of sufficient PEEP and ARMs.

Far from this pulmonary pathology, any mechanically ventilated patient, whether in the ICU or operating theatre, must benefit from a protective strategy. Any inadequate adjustment of the ventilation parameters can lead to lung lesions induced by mechanical ventilation (VILI, Ventilator Induced Lung Injuries) and to lesions similar to those observed during ARDS.

We therefore propose to explore the impact on pulmonary aeration and ventilatory parameters of two different strategies of PEEP optimization during invasive mechanical ventilation in healthy lungs and ARDS ICU patients. This randomized controlled study would allow us to validate our hypotheses, depending on the respiratory mechanics and patient's pulmonary disease.The final aim of this study is to determine the effects of a strategy based on the application of an ARM followed by decremental PEEP titration, compared to an incremental PEEP strategy without ARM, on pulmonary and ventilatory physio-(patho)-logical parameters in ICU patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ICU Patients Healthy Lung Positive End-Expiratory Pressure ARDS Alveolar Recruitment Maneuver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Interventional trial comparing two strategies of PEEP optimization during mechanical ventilation in two groups of ICU patients: with healthy lungs or with ARDS. The study consists of comparing pulmonary pathophysiological parameters for different PEEP levels. The first strategy implies the use of an ARM followed by a stepwise decremental PEEP titration whereas the second considers a stepwise incremental PEEP titration without any previous ARM, during controlled invasive mechanical ventilation. Each patient will receive both strategies in a random consecutive order
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Statistical analysis will be conducted by an independant statistician not involved in data collection

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Decremental PEEP titration following an ARM

PEEP will be titrated in a stepwise decremental fashion following a standardized alveolar recruitment maneuver (ARM). The ARM is a progressive increase of intra-thoracic pressure (pressure controlled mode), with a constant driving pressure of 10 cmH2O and PEEP steps (10-15-20-25-30-35 and 40 cmH2O), reaching a maximum pressure of 50 cmH2O, allowing full recruitment. PEEP steps will be conducted every 2 cmH2O (from 20 to 6 cmH2O), every 5 minutes.

Group Type ACTIVE_COMPARATOR

Decreasing PEEP setting

Intervention Type OTHER

End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.

Incremental PEEP titration without any previous ARM

PEEP will be titrated in a stepwise incremental fashion without any previous alveolar recruitment maneuver (ARM). PEEP steps will be conducted every 2 cmH2O (from 6 to 20 cmH2O), every 5 minutes.

Group Type ACTIVE_COMPARATOR

Increasing PEEP setting

Intervention Type OTHER

End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Increasing PEEP setting

End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.

Intervention Type OTHER

Decreasing PEEP setting

End expiratory lung volume and lung aeration measurements will be conducted using electrical impedance tomography and nitrogen washin-washout method. Measurements will be conducted during the last minute of each step.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient over 18 years of age
* ICU patients with healthy lungs or lungs with Acute Respiratory Distress Syndrome (according to Berlin criteria) under mechanically invasive controlled ventilation (intubation or tracheotomy) in the early phase of admission (\< 12h)
* Patient deeply sedated (BIS between 30 and 50) and possibly under neuromuscular blocking agents (TOF \< 2/4 at the orbicular) in case of inspiratory efforts
* Patient hemodynamically stable with an optimized volemia using a monitoring system (see protocol).
* Consent to participate
* Patient benefiting from a Social Security Insurance

Exclusion Criteria

* Refusal to participate to the proposed study
* Obese patient with BMI ≥ 35 kg.cm-2
* Significant hemodynamic instability defined as \> 20% increase in catecholamine doses during the last hour, despite optimization of blood volume according to a pre-established protocol
* Contraindication to the use of the electro-impedance tomography technique

* Thoracic lesions
* Chest bandages
* Pace-maker/Implantable defibrillator
* Contraindication to the performance of an alveolar recruitment maneuver

* Major Emphysema
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Godet

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU

Clermont-Ferrand, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lise Laclautre

Role: CONTACT

+33 4 73 754963

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Thomas Godet

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RBHP 2019 GODET (Peep Réa)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.